Date | Title | Description | |
---|---|---|---|
08 May 2024 | On P&L | The Company releases the first three months 2024 financial results presentation | Download |
25 Apr 2024 | On business and financial situation | ROVI announces agreement to manufacture pre-filled syringes | Download |
27 Feb 2024 | About Corporate Governance | The Company informs about the agreements adopted by the Board of Directors | Download |
27 Feb 2024 | On P&L | The Company releases the press release related to the full year 2023 financial results. | Download |
27 Feb 2024 | On P&L | The Company releases the full year 2023 financial results presentation. | Download |
Pages
Date | Title | Description | |
---|---|---|---|
24 Feb 2021 | On business and financial situation | ROVI releases the 2020 Results presentation | Download |
24 Feb 2021 | Annual Corporate Governance Report | ROVI releases the 2020 Annual Corporate Governance Report | Download |
24 Feb 2021 | Annual Report regarding remuneration of the members of the Board of Directors | ROVI releases the 2020 annual report regarding remuneration of the members of the Board of Directors | Download |
11 Jan 2021 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the fourth quarter of 2020 | Download |
24 Nov 2020 | On business and financial situation | The Company releases the presentation related to its strategy update because of the 2020 Capital Markets Day. | Download |
Pages
Date | Title | Description | |
---|---|---|---|
08 Jan 2018 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the fourth quarter of 2017 | Download |
21 Dec 2017 | Préstamos, créditos y avales | ROVI and the EIB agree to sign a loan to boost research into drug administration and prolonged-release technologies | Download |
08 Nov 2017 | Información sobre Resultados | ROVI releases the press release related to the nine-month period ended 30 September 2017 results | Download |
08 Nov 2017 | Información sobre Resultados | ROVI releases the presentation related to the nine-month period ended 30 September 2017 results. | Download |
24 Oct 2017 | Otros sobre negocio y situación financiera | The Company releases the presentation related to the update of its Phase III-Prima 3 Risperidone ISM® project. | Download |